News &
Publications

Pinion's newsroom: company announcements, peer-reviewed publications, and where to find the team. Three subsections below.

Press Releases

Scientific visualization supporting Pinion Immunotherapeutics ARV-2001 HPV-16 immunotherapy research

August 28, 2026

Press Release

August 28, 2026

Pinion Immunotherapeutics Publishes Preclinical Data Supporting Clinical-Ready RNA Immunotherapy for HPV-16 Cervical Precancer

Pinion Immunotherapeutics has published preclinical data supporting ARV-2001, its lead RNA immunotherapy, in the peer-reviewed journal Vaccines.

Scientific visualization of targeted cervical tissue associated with ARV-2001 HPV-16 research

2026

Vaccines

2026 | Vaccines

Preclinical Development of ARV-2001, an Intradermally Administered mRNA–Lipid Nanoparticle Immunotherapeutic for the Treatment of HPV-16-Positive Cervical High-Grade Squamous Intraepithelial Lesions.

Cervical cancer remains a leading cause of cancer death among women worldwide and is almost exclusively attributable to persistent infection with high-risk human papillomavirus (HPV) genotypes, of which HPV-16 is the most prevalent and most oncogenic...

View publication

Scientific visualization of an mRNA-loaded lipid nanoparticle delivery system

2025

Int J Nanomedicine

2025 | Int J Nanomedicine

Lipid Nanoparticles Formulated with a Novel Cholesterol-Tailed Ionizable Lipid Markedly Increase mRNA Delivery Both in vitro and in vivo.

The development of novel ionizable lipids holds great promise in improving the efficacy and safety of LNPs.Methods: We synthesized a novel ionizable lipid, ARV-T1, with a cholesterol moiety incorporated in its tail...

View publication

News & Publications

Press Releases

Publications

Pinion Immunotherapeutics

News &
Publications